PMID- 25605060
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Mar
TI  - Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but 
      time?
PG  - 453-6
LID - 10.1517/14656566.2015.994505 [doi]
AB  - Glycosuria is being increasingly recognised as not only a symptom but also as a 
      novel therapeutic approach in the management of type 2 diabetes mellitus (T2DM). 
      This is accomplished through sodium glucose co-transporter 2 (SGLT2) inhibitors. 
      Consequently, the safety and efficacy of these new agents have been thoroughly 
      studied, both in randomised controlled trials and in systematic reviews and 
      meta-analyses. More recently, a review on the mechanism of action, clinical 
      efficacy and safety of luseogliflozin, a new highly selective SGLT2 inhibitor 
      approved and launched in Japan for T2DM, has documented that this drug lowers 
      plasma glucose concentration and body weight, and that it exhibits benefits in 
      other metabolic parameters with a good safety profile. Despite the promising 
      characteristics of this drug, important issues await consideration. These include 
      the question as to when and to whom early use of SGLT2 inhibitors would be most 
      suitable, as well as instructions on reduction of sulfonylurea dosage during 
      add-on treatment. Further important questions are long-term safety concerns and 
      cost-effectiveness of this new therapeutic class. Finally, we need to know more 
      about the potential differences between the various SGLT2 inhibitors, as such 
      differences might prove clinically useful in selection of hypoglycaemic agents.
FAU - Pafili, Kalliopi
AU  - Pafili K
AD  - Democritus University of Thrace, University Hospital of Alexandroupolis, Diabetes 
      Clinic, Second Department of Internal Medicine , G. Kondyli 22c, Alexandroupolis 
      68100 , Greece papanasnikos@yahoo.gr.
FAU - Papanas, Nikolaos
AU  - Papanas N
LA  - eng
PT  - Editorial
DEP - 20150120
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 506T60A25R (Sorbitol)
RN  - C596HWF74Z 
      (1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
MH  - Sorbitol/*analogs & derivatives/therapeutic use
OTO - NOTNLM
OT  - diabetes mellitus
OT  - luseogliflozin
OT  - oral hypoglycaemic agents
OT  - sodium-glucose transport inhibitors
OT  - therapy.
EDAT- 2015/01/22 06:00
MHDA- 2015/06/16 06:00
CRDT- 2015/01/22 06:00
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 10.1517/14656566.2015.994505 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2015 Mar;16(4):453-6. doi: 
      10.1517/14656566.2015.994505. Epub 2015 Jan 20.